Okay kiddo, so this article is talking about a big company called Amgen that makes medicines for people who are sick. Some rich and smart people think this company will do well in the future, so they are buying lots of its shares. The price of these shares has gone down a bit, but some experts still believe it's worth more and will go up again soon. They have given numbers to show how much they think each share is worth. Read from source...

- The title is misleading and sensationalized, implying that only whales are betting on Amgen, while the article does not provide any evidence or data to support this claim.
- The author uses vague terms like "whales" and "insiders" without defining them or explaining their relevance to the readers.
- The article focuses too much on options activities and trading volume, which are not reliable indicators of a stock's future performance or value. They also do not reflect the actual demand or interest for Amgen's products or services.
- The author does not provide any critical analysis of Amgen's business model, strategy, competition, or risks, nor does he/she mention any of the company's recent developments or challenges.
- The article relies heavily on secondary sources and expert opinions, without questioning their credibility, motives, or conflicts of interest. It also fails to present any contrasting views or alternative perspectives.
- The author uses emotional language and exaggerated statements, such as "may be approaching oversold" or "consistent in their evaluation", which do not add any value or insight to the readers. They also create a sense of urgency and uncertainty, which may influence the readers' decisions without providing any solid evidence or reasoning.
- The article does not provide any clear conclusion or recommendation, nor does it offer any actionable advice or tips for the readers who are interested in investing in Amgen. It ends abruptly with a mention of an analyst from Morgan Stanley, which leaves the readers hanging and confused.

The most important takeaway is that Amgen is a company that operates in the biotechnology industry, which is known for being volatile and having high risks. However, it also offers potential rewards for investors who are willing to tolerate some risk. Based on the information provided, I would recommend the following:

1. Buy AMGN at its current price of $288.1, as it is approaching oversold territory and has strong support from analysts with positive ratings and target prices. This could provide an opportunity for a bounce back in the short term. However, be prepared for some fluctuations in the stock price due to the nature of the industry.
2. Hold AMGN for the long term, as it has a strong pipeline of drugs and a growing biosimilar portfolio that could generate consistent revenue growth and increase shareholder value over time. Additionally, Amgen has a history of paying dividends, which could provide some income for investors who are looking for passive income.
3. Diversify your portfolio by investing in other biotechnology stocks or ETFs that focus on the sector, such as iShares NASDAQ Biotechnology Index (IBB) or SPDR S&P Biotech ETF (XBI). This could help you to benefit from the overall growth of the industry and reduce the risk of relying solely on one stock.
4. Monitor the news and earnings reports for Amgen, as well as any changes in the regulatory environment or competitive landscape that could impact the company's performance. This could provide clues about future opportunities or risks for investors.